{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-004461","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2023-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.954615+00:00","generated_at":"2026-06-20T14:04:51.946820+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroBo CEO Gil Price resigns; Joseph Hooker named Interim CEO","bullets":["Gil Price resigned as CEO and President effective Jan 12, 2023; resignation not due to disagreement.","Joseph Hooker appointed Interim CEO, President, and Principal Financial and Accounting Officer.","Hooker brings ~40 years pharma experience; previously at X4 Pharma, Biogen, Novartis.","Board to initiate permanent CEO search with executive search firm.","Company advancing DA-1241 and DA-1726; completed $32.3M financing in Nov 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-004461","json":"https://secwatch.observer/filing/0001104659-23-004461.json","markdown":"https://secwatch.observer/filing/0001104659-23-004461.md","text":"https://secwatch.observer/filing/0001104659-23-004461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465923004461/0001104659-23-004461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465923004461/tm233671d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T14:04:51.946820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"268a45665e","claim":"Joseph Hooker was appointed as Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer at MetaVia Inc..","evidence_excerpt":"On January 12, 2023, the Board appointed Joseph Hooker as the Company’s Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, effective as of January 12 , 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465923004461/0001104659-23-004461-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"aad294fe4b","claim":"Gil Price resigned as Chief Executive Officer and President at MetaVia Inc..","evidence_excerpt":"On January 12, 2023, Gil Price, M.D. resigned as Chief Executive Officer and President of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465923004461/0001104659-23-004461-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}